|
Schizophrenia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Our objective was to use Mendelian randomization to evaluate whether SZ increased risk for developing EOC or the converse, and, whether SZ impacted 1- or 2-glycerophosphocholine (1- or 2-GPC) metabolites.
|
31844628 |
2019 |
|
Hypoxic-Ischemic Encephalopathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
During therapeutic hypothermia, neonates with severe HIE had decreased basal ganglia N-acetylaspartate (NAA; 0.62±0.08 vs. 0.72±0.05; P=0.02), NAA + N-acetylaspartylglutamate (NAAG; 0.66±0.11 vs. 0.77±0.06; P=0.05), glycerophosphorylcholine + phosphatidylcholine (GPC+PCh; 0.28±0.05 vs. 0.38±0.06; P=0.02) and decreased white matter GPC+PCh (0.35±0.13 vs. 0.48±0.04; P=0.02) compared to neonates with moderate HIE.
|
30918993 |
2019 |
|
Arteriosclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The serum metabonomics study showed that the LDLR<sup>-/-</sup> ,PSGL-1<sup>-/-</sup> mice had higher levels of HDL, valine, acetate, pyruvate, choline, PC, GPC and glycine, and lower levels of LDL+VLDL and lactate at the early stage of atherosclerosis, while lactate, citrate and glutamine showed statistical significance at the late stage of atherosclerosis.
|
29483823 |
2018 |
|
Atherosclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The serum metabonomics study showed that the LDLR<sup>-/-</sup> ,PSGL-1<sup>-/-</sup> mice had higher levels of HDL, valine, acetate, pyruvate, choline, PC, GPC and glycine, and lower levels of LDL+VLDL and lactate at the early stage of atherosclerosis, while lactate, citrate and glutamine showed statistical significance at the late stage of atherosclerosis.
|
29483823 |
2018 |
|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Choline alfoscerate (α-GPC) is a common choline compound and acetylcholine precursor in the brain, which has been shown to be effective in the treatment of Alzheimer's disease and dementia.
|
27765578 |
2017 |
|
Presenile dementia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Choline alfoscerate (α-GPC) is a common choline compound and acetylcholine precursor in the brain, which has been shown to be effective in the treatment of Alzheimer's disease and dementia.
|
27765578 |
2017 |
|
Mental Depression
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, currently available evidence was of low quality and therefore inadequate to justify a strong recommendation of using GPD formulations in the management of depression.
|
26453561 |
2017 |
|
Depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, currently available evidence was of low quality and therefore inadequate to justify a strong recommendation of using GPD formulations in the management of depression.
|
26453561 |
2017 |
|
Hemorrhagic Fever, Argentinian
|
0.010 |
Biomarker
|
disease |
BEFREE |
We have previously shown that the Can glycoprotein (GPC) gene is the primary gene responsible for attenuation in a guinea pig model of AHF.
|
28220142 |
2017 |
|
Meningitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
There was elevation in the levels of ketone bodies, total free amino acids, glutamine, creatine, citrate and choline containing compounds (choline and GPC) in meningitis cases.
|
28315295 |
2017 |
|
Cerebrovascular accident
|
0.010 |
Biomarker
|
group |
BEFREE |
α-GPC has been shown to enhance memory and cognitive function in stroke and Alzheimer's patients but currently remains untested in patients suffering from epilepsy.
|
27765578 |
2017 |
|
Depressed mood
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
However, currently available evidence was of low quality and therefore inadequate to justify a strong recommendation of using GPD formulations in the management of depression.
|
26453561 |
2017 |
|
Dementia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Choline alfoscerate (α-GPC) is a common choline compound and acetylcholine precursor in the brain, which has been shown to be effective in the treatment of Alzheimer's disease and dementia.
|
27765578 |
2017 |
|
Virus Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
This finding has uncovered novel viral determinants of viral persistence, and a detailed characterization of rCl-13(GPC/VGKS) can provide novel insights into the mechanisms underlying persistent viral infection.
|
27581982 |
2016 |
|
Lymphocytic Choriomeningitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Evolution of recombinant lymphocytic choriomeningitis virus/Lassa virus in vivo highlights the importance of the GPC cytosolic tail in viral fitness.
|
24829355 |
2014 |
|
Malaria, Vivax
|
0.010 |
Biomarker
|
disease |
BEFREE |
Glycophorin C (CD236R) mediates vivax malaria parasite rosetting to normocytes.
|
24652986 |
2014 |
|
Non-arthropod borne lymphocytic choriomeningitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Evolution of recombinant lymphocytic choriomeningitis virus/Lassa virus in vivo highlights the importance of the GPC cytosolic tail in viral fitness.
|
24829355 |
2014 |
|
Psychotic symptom
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Anterior cingulate GPC+PC and caudate Glu+Gln were significantly correlated with attenuated psychotic symptom severity.
|
23791389 |
2013 |
|
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Both serum GPC-3 and GPC-3mRNA are promising diagnostic markers for early detection of HCC in Egyptian patients.
|
24460300 |
2013 |
|
Glioblastoma Multiforme
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We tapped into public sources of GPC gene expression data and derived a gene signature distinguishing oligodendroglial from glioblastoma multiforme (GBM) GPCs.
|
22675171 |
2012 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
[Relationship between expression of GYPC and TRIP3 genes and prognosis of acute lymphoblastic leukemia in children].
|
19149918 |
2009 |
|
Conjunctivitis, Giant Papillary
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The study groups comprised 13 patients (13 eyes) with vernal keratoconjunctivitis (VKC group), 13 patients (13 eyes) with atopic keratoconjunctivitis (AKC group), 11 patients (11 eyes) with giant papillary conjunctivitis (GPC group), and 10 healthy volunteers (10 eyes) as a control.
|
17926108 |
2007 |
|
Keratoconjunctivitis, Vernal
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The study groups comprised 13 patients (13 eyes) with vernal keratoconjunctivitis (VKC group), 13 patients (13 eyes) with atopic keratoconjunctivitis (AKC group), 11 patients (11 eyes) with giant papillary conjunctivitis (GPC group), and 10 healthy volunteers (10 eyes) as a control.
|
17926108 |
2007 |
|
Atopic keratoconjunctivitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The study groups comprised 13 patients (13 eyes) with vernal keratoconjunctivitis (VKC group), 13 patients (13 eyes) with atopic keratoconjunctivitis (AKC group), 11 patients (11 eyes) with giant papillary conjunctivitis (GPC group), and 10 healthy volunteers (10 eyes) as a control.
|
17926108 |
2007 |
|
Yellow Fever
|
0.010 |
Biomarker
|
disease |
BEFREE |
The Yellow Fever Vaccine 17D (YFV17D) has been used as a vector for the Lassa virus glycoprotein precursor (LASV-GPC) resulting in construction of YFV17D/LASV-GPC recombinant virus.
|
16412488 |
2006 |